Side effects and complications of amiodarone therapy☆
References (51)
- et al.
Amiodarone therapy in symptomatic, sustained refractory atrial and ventricular tachyarrhythmias
Am Heart J
(1981) - et al.
Clinical efficacy of amiodarone as an antiarrhythmic agent
Am J Cardiol
(1976) - et al.
Possible association of pneumonitis with amiodarone therapy
Am Heart J
(1980) - et al.
Maximum usage of the life table method in analyzing survival
J Chron Dis
(1958) - et al.
Amiodarone for control of sustained ventricular tachyarrhythmia: Clinical and electrophysiologic effects in 51 patients
Am J Cardiol
(1982) - et al.
Amiodarone pulmonary toxicity
Am Heart J
(1983) - et al.
Amiodarone-digoxin interaction: Clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications
J Am Coll Cardiol
(1984) - et al.
Dangerous interaction between amiodarone and quinidine
Lancet
(1982) - et al.
Evaluation of amiodarone therapy in the treatment of drug resistant cardiac arrhythmias. Long-term follow-up
Am Heart J
(1983) - et al.
Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone
Am Heart J
(1981)
Amiodarone-induced polymorphous ventricular tachycardia
Am Heart J
Ventricular flutter during treatment with amiodarone
Am J Cardiol
Amiodarone and neurological side effects
Lancet
Long-term use of procainamide following acute myocardial infarction
Circulation
Congestive heart failure caused by oral disopyramide
N Engl J Med
Ranitidine or cimetidine
Ann Intern Med
Side effects of long-term amiodarone therapy
Circulation
Amiodarone increases plasma digoxin concentrations
Br Med J
Interaction between warfarin sodium and amiodarone
N Engl J Med
Pharmacokinetics of amiodarone after intravenous and oral administration
Eur J Clin Pharmacol
SAS user's guide: Statistics
Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias
Circulation
Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation
N Engl J Med
Alveolitis after treatment with amiodarone
Br Med J
Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: A possible complication of a new antiarrhythmic drug
Circulation
Cited by (188)
Prevalence of amiodarone-induced hypothyroidism; A systematic review and meta-analysis
2023, Trends in Cardiovascular MedicineIs amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation?
2022, Revista Portuguesa de CardiologiaCLInical Profile and Side Effects of chronic use of oral Amiodarone in cardiology outpatients department (CLIPSE-A Study)- A prospective observational study
2022, Annals of Medicine and SurgeryCitation Excerpt :Amiodarone is not indicated for persons with second or third-degree heart block who do not have pacemakers. Amiodarone should be avoided in those who have a baseline QTc prolongation [28,29]. Although retrospective investigations have shown that iodine or iodinated contrast agent allergies are not an absolute contraindication to amiodarone, the incidence of hypersensitivity reactions to amiodarone in people who have been diagnosed with iodine allergies should be closely monitored [30,31].
Amiodarone treatment in atrial fibrillation and the risk of incident cancers: A nationwide observational study
2020, Heart RhythmCitation Excerpt :Previous studies have generally been limited by sample size, however, using a large cohort with long-term follow-up and nationwide coverage, we did not find any associations between amiodarone therapy and incident cancers. Our results suggest that even though amiodarone is associated with a relatively high risk of organ toxicity, which manifests especially after prolonged treatment, this is not reflected in cancer occurrence in patients with AF.22,28,29 The major limitations of the study are inherent to the observational study design, the potential for bias, and the inability to draw causal conclusions.
Amiodarone-induced optic neuropathy: A rare side effect
2019, Revue de Medecine Interne“Blue-grey syndrome” – A rare adverse effect of amiodarone
2018, Cor et Vasa
- ☆
Supported by the Rappaport International Cardiovascular Program and by Grant No. HL-07776 from the National Heart, Lung, and Blood Institute, National institutes of Health, United States Public Health Service, Bethesda, Md.